These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39295614)

  • 1. Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT.
    Çelik B; Peker Eyüboğlu İ; Koca S; Uğurlu MÜ; Alan Ö; Güllü Amuran G; Akin Telli T; Yumuk F; Akkiprik M
    Turk J Med Sci; 2024; 54(4):652-665. PubMed ID: 39295614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
    Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
    Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of circulating cell-free mtDNA in patients with suspected thyroid cancer: ND4/ND1 ratio as a new potential plasma marker.
    Jiang Z; Bahr T; Zhou C; Jin T; Chen H; Song S; Ikeno Y; Tian H; Bai Y
    Mitochondrion; 2020 Nov; 55():145-153. PubMed ID: 33035689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
    Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
    Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY; Wu S; Ma X; Liu Y
    Breast Cancer Res Treat; 2024 Oct; 207(3):517-527. PubMed ID: 38990453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Circulating Cell-Free DNA in Idiopathic Parkinson's Disease Patients.
    Wojtkowska M; Karczewska N; Pacewicz K; Pacak A; Kopeć P; Florczak-Wyspiańska J; Popławska-Domaszewicz K; Małkiewicz T; Sokół B
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
    Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
    Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis.
    Huebner H; Lubrich H; Blum S; Antoniadis S; Lermann J; Ekici A; Fasching PA; Beckmann MW; Ruebner M; Burghaus S
    Reprod Biomed Online; 2021 Nov; 43(5):788-798. PubMed ID: 34493460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
    Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
    Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology.
    Panagopoulou M; Karaglani M; Tzitzikou K; Kessari N; Arvanitidis K; Amarantidis K; Drosos GI; Gerou S; Papanas N; Papazoglou D; Baritaki S; Constantinidis TC; Chatzaki E
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients.
    Saucedo-Sariñana AM; Lugo-Escalante CR; Barros-Núñez P; Marín-Contreras ME; Pineda-Razo TD; Mariscal-Ramírez I; Gallegos-Arreola MP; Rosales-Reynoso MA
    Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):1-8. PubMed ID: 36227685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer.
    Keserű JS; Soltész B; Lukács J; Márton É; Szilágyi-Bónizs M; Penyige A; Póka R; Nagy B
    J Biotechnol; 2019 Jun; 298():76-81. PubMed ID: 31002856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.